Glyphic Biotechnologies
PrivateLast Round
Series A
Feb 16, 2024
Total Funding Raised
$39.99M
Company Overview
Glyphic Biotechnologies operates in Healthcare & Life Sciences and is based in Berkeley, California. Its latest recorded funding round was a Series A round in February 2024.
Glyphic Biotechnologies is a biotechnology company that develops a single-molecule, massively parallel, de novo next-generation protein sequencing platform to enable novel therapeutics and diagnostics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Glyphic Biotechnologies Comparables
Compare Glyphic Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Erisyon | 86% | |
| Encodia | 86% | |
| Quantum-Si | 86% |
For institutional investors. Book with your work email.
Glyphic Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 16, 2024 | ||||
| Grant | Sep 15, 2023 | ||||
| Grant | Sep 6, 2022 | ||||
| Seed | Jul 8, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Glyphic Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Zeon Ventures | Series A |
| NIH RADx | Grant |
| Cantos Ventures | Seed |
| Gaingels | Seed |
| FoundersX Ventures | Series A, Seed |
| ARTIS Ventures | Series A, Seed |
| Osage University Partners | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 16, 2024
$33M round completed.
- Sep 15, 2023
$359K grant received from NIH RADx.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueAug 10, 2026
Glyphic Biotechnology, Inc. has an estimated $4.5M in revenue in Jun '24.
For institutional investors. Book with your work email.
Glyphic Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Glyphic Biotechnologies's valuation, stock price, and market status.
Is Glyphic Biotechnologies a public or private company?
Glyphic Biotechnologies is a private company.
What is the current stock price of Glyphic Biotechnologies?
Glyphic Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Glyphic Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Glyphic Biotechnologies worth (valuation)?
Valuation information for Glyphic Biotechnologies is not publicly available.
Can I buy Glyphic Biotechnologies stock?
Glyphic Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Glyphic Biotechnologies's last funding round?
Glyphic Biotechnologies's most recent funding round was Series A on February 16, 2024.
Who are the main investors in Glyphic Biotechnologies?
Key investors in Glyphic Biotechnologies include LongeVC, OMX Ventures.
Will Glyphic Biotechnologies IPO soon?
No public IPO plans have been announced for Glyphic Biotechnologies.
How can I track Glyphic Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Glyphic Biotechnologies's shares on secondary markets.